ANI Pharmaceuticals Corp (ANIP) - Long-Term Debt to Capital Coefficient

ANI Pharmaceuticals Corp - graphic logo of issuer ANIP

The ANI Pharmaceuticals ecosystem relies on the stable supply of hospitals and pharmacies through the flexible production of niche generics. This price chart illustrates the trend of the indicator, which currently stands at 0.94. Steady cash flow and high margins on orphan drugs guarantee profit reliability, while the expansion of specialized gels and fresh product lines create a powerful growth impulse.

ANI Pharmaceuticals Inc (ANIP): Long-Term Debt to Equity from 07/04/2022 to 10/30/2026
Signature product of ANI Pharmaceuticals

Investors are assessing the resilience of ANI Pharmaceuticals (ANIP) by analyzing long-term leverage, which measures credit obligations exceeding one year relative to shareholders' equity. The trend in the long-term debt-to-equity ratio demonstrates how effectively the generics portfolio finances expansion without critical debt burdens, determining the balance between financial leverage and the issuer's solvency.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Liquidia Inc.|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital mannkindcorp.com|Long-Term Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Long-Term Liabilities to Capital|AQST: Long-Term Debt to Equity Ratio|scPharmaceuticals Inc. - Long-Term Loans to Capital Ratio|TECX: Long-Term Debt to Capital|Tonix Pharma - Long-Term Debt to Capital Coefficient|SXTC (SXT Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Eupraxia Pharma EPRX|Long-Term Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ORMP (Oramed Pharmaceuticals Inc.)|Long-Term Debt to Capital Entera Bio Ltd ENTX|HYFT - Long-Term Debt to Equity|ABVC (ABVC BioPharma, Inc) - Long-Term Debt to Capital Ratio|CPIX: Long-Term Debt to Capital|QNTM - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio FGEN|TELO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Rani Therapeutics (RANI)|SNYR: Long-Term Liabilities to Equity|Long-Term Debt to Capital RLYB (Rallybio)|Long-Term Debt to Capital Coefficient LEXX|Pulmatrix - Long-Term Debt to Capital|PTHL - Long-Term Debt to Capital|aptorumgroup.com (APM) - Long-Term Debt to Equity|Lyra Therapeutics Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Impact BioMedical Inc|Long-Term Debt to Equity Ratio TNF Pharma (TNFA)|Long-Term Debt to Capital YCBD|Long-Term Debt to Capital PainReform Ltd (PRFX)|Long-Term Debt to Capital CYTO (Altamira Therapeutics Ltd.)|LIPO - Long-Term Debt to Equity Ratio|OptiNose, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital pieris.com|PROC (Procaps) - Long-Term Debt to Equity Ratio|Petros Pharmaceuticals Inc (PTPI) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio QLI|SLRN (ACELYRIN Inc.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital TFFP